Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection

Virology

Volumn 414, Issue 2, 2011, Pages 146-152

  Hunt, Ann R ^a   Bowen, Richard A ^a   Frederickson, Shana ^b   Maruyama, Toshiaki ^c   Roehrig, John T ^d   Blair, Carol D ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b Alexion Antibody Technologiesm Inc   (United States)

^c Alexion Antibody Technologies Inc   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Alphavirus; Antibody prophylaxis; Antibody therapy; Envelope glycoprotein; Human monoclonal antibody; Venezuelan equine encephalitis virus

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F5 NIGG; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS RNA;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG DOSE COMPARISON; EARLY INTERVENTION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RNA ANALYSIS; SURVIVAL RATE; VENEZUELAN EQUINE ENCEPHALITIS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; FEMALE; HUMANS; MALE; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; POST-EXPOSURE PROPHYLAXIS; VIRAL ENVELOPE PROTEINS; VIRULENCE;

ALPHAVIRUS; ANIMALIA; MUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 79955927334     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.03.016     Document Type: Article

References (46)

1. Bakker A.B.H., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., Lagerwerf F., Worst S., van Corven E., Kostense S., Hartmann K., Weverling G.Jl, Uytdehaag F., Herzog C., Briggs D.J., Rupprecht C.E., Grimaldi R., Goudsmit J. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922-5927.
2. Beigel J.H., Nordstrom J.L., Pillemer S.R., Roncal C., Goldwater D.R., Li H., Holland P.C., Johnson S., Stein K., Koenig S. Safety and pharmacokinetics of single intraveneous dose of MGAWM1, a novel monoclonal antibody to West Nile virus. Antimicrob. Agents Chemother. 2010, 54:2431-2436.
3. Bronze M.S., Huycke M.M., Machado L.J., Voskuhl G.W., Greenfield R.A. Viral agents as biological weapons and agents of bioterrorism. Am. J. Med. Sci. 2002, 323:316-325.
4. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 2002, 8:333-341.
5. Casadevall A., Dadachova E., Pirofski L.-A. Passive antibody therapy for infectious diseases. Nat. Rev. 2004, 2:695-703.
6. Charles P.C., Brown K.W., Davis N.L., Hart M.K., Johnston R.E. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology 1997, 228:153-160.
7. Charles P.C., Trgovcich J., Davis N.L., Johnston R.E. Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-induced disease in the mouse. Virology 2001, 284:190-202.
8. Elvin S.J., Bennett A.M., Phillpotts R.J. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J. Med. Virol. 2002, 67:384-393.
9. Fine D.L., Roberts B.A., Terpening S.J., Mott J., Vasconcelos D., House R.V. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine 2008, 26:3497-3506.
10. Griffin D.E. Recovery from viral encephalomyelitis: immune-mediated noncytolytic virus clearance from neurons. Immunol. Res. 2010, 47:123-133.
11. Hart M.K., Caswell-Stephan K., Bakken R., Tamariello R., Pratt W., Davis N., Johnston R.E., Smith J., Steele K. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated v3526 vaccine candidate. Vaccine 2000, 18:3067-3075.
12. Hawley R.J., Eitzen E.M. Biological weapons-a primer for microbiologists. Annu. Rev. Microbiol. 2001, 55:235-253.
13. Hunt A.R., Frederickson S., Hinkel C., Bowdish K.S., Roehrig J.T. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J. Gen. Virol. 2006, 87:2467-2476.
14. Hunt A.R., Frederickson S., Maruyama T., Roehrig J.T., Blair C.D. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl. Trop. Dis. 2010, 4:e739.
15. Jackson A.C., SenGupta S.K., Smith J.F. Pathogenesis of Venezuelan equine encephalitis virus infection in mice and hamsters. Vet. Pathol. 1991, 28:410-418.
16. Jahrling P.B., Stephenson E.H. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus against aerosol challenge in hamsters. J. Clin. Microbiol. 1984, 19:429-431.
17. Johnson K.M., Martin D.H. Venezuelan equine encephalitis. Adv. Vet. Sci. Comp. 1974, 18:79-116.
18. Johnston R.E., Peters C.J. Alphaviruses. Virology 1996, 843-898. Lippincott-Raven Press, New York. B.N. Fields, D.M. Knipe, P.M. Howley, R.M. Channock, J.L. Melnick, T.P. Monath, B. Roizman (Eds.).
19. Kinney R.M., Esposito J.J., Johnson B.J.B., Roehrig J.T., Mathews J.H., Barrett A.D.T., Trent D.W. Recombinant vaccinia-Venezuelan equine encephalitis (VEE) virus expresses VEE structural proteins. J. Gen. Virol. 1988, 69:3005-3013.
20. Krause R.M., Dimmock N.J., Morens D.M. summary of antibody workshop: the role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J. Infect. Dis. 1997, 176:549-559.
21. Kundin W.D. Pathogenesis of Venezuelan equine encephalomyelitis virus II. Infection in young and adult mice. J. Immunol. 1966, 96:49-58.
22. Levine B., Griffin D.E. Persistence of viral RNA in mouse brains after recovery from acute alphavirus encephalitis. J. Virol. 1992, 66:6429-6435.
23. Levine B., Hardwick J.M., Trapp B.D., Crawford T.O., Bollinger R.C., Griffin D.E. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991, 254:856-860.
24. Mathews J.H., Roehrig J.T. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J. Immunol. 1982, 129:2763-2767.
25. Mathews J.H., Roehrig J.T., Trent D.W. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J. Virol. 1985, 55:594-600.
26. Obijeski J.F., Bishop D.H., Murphy F.A., Palmer E.L. Structural proteins of La Crosse virus. J. Virol. 1976, 19:985-997.
27. Paessler S., Ni H., Petrakova O., Fayzulin R.Z., Yun N., Anishchenko M., Weaver S.C., Frolov I. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J. Virol. 2006, 80:2784-2796.
28. Phillpotts R.J. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I II and III. Virus Res. 2006, 120:107-112.
29. Phillpotts R.J., Jones L.D., Howard S.C. Monoclonal antibody protects mice against infection and disease when given either before or up to 24h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 2002, 20:1497-1504.
30. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996, 14:337-343.
31. Pratt W.D., Davis N.L., Johnston R.E., Smith J.F. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 2003, 21:3854-3862.
32. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Epidem. 1938, 27:493-497.
33. Reed D.S., Lind C.M., Lackemeyer M.G., Sullivan L.J., Pratt W.D., Parker M.D. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine 2005, 23:3139-3147.
34. Roehrig J.T., Corser J.A., Schlesinger M. Isolation and characterization of hybrid cell lines producing monoclonal antibodies directed against the structural proteins of Sindbis virus. Virology 1980, 101:41-49.
35. Roehrig J.T., Day J.W., Kinney R.M. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 1982, 118:269-278.
36. Roehrig J.T., Mathews J.H. The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. Virology 1985, 142:347-356.
37. Ryzhikov A.B., Ryabchikova E.I., Sergeev A.N., Tkacheva N.V. Spread of Venezuelan equine encephalitis virus in mice olfactory tract. Arch. Virol. 1995, 140:2243-2254.
38. Sanna P.P., Ramiro-Ibanez F., De Logu A. Synergistic interactions of antibodies in rate of virus neutralization. Virology 2000, 270:386-396.
39. Slepushkin A.N. Epidemiological studies on case of Venezuelan equine encephalomyelitis in a laboratory. Vop. Virulsol. 1959, 4:311-314.
40. The Subcommittee on Arbovirus Laboratory Safety of the American Committee on Arthropod-borne Viruses Laboratory safety for arboviruses and certain other viruses of vertebrates. Am. J. Trop. Med. Hyg. 1980, 29:1359-1381.
41. Ubol S., Levine B., Lee S.-H., Greenspan N.S., Griffin D.E. Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated downregulation of Sindbis virus replication in persistently infected neurons. J. Virol. 1995, 69:1990-1993.
42. Weaver S.C., Ferro C., Barrera R., Boshell J., Navarro J.-C. Venezuelan equine encephalitis. Annu. Rev. Entomol. 2004, 49:141-174.
43. Weaver S.C., Reisen W.K. Present and future arboviral threats. Antiviral Res. 2010, 85:328-345.
44. Weltzin R., Monath T.P. Intranasal antibody prophylaxis for protection against viral disease. Clin. Microbiol. Rev. 1999, 12:383-393.
45. Zarate M.L., Scherer W.F. Contact-spread of Venezuelan equine encephalitis virus among cotton rats via urine or feces and the naso- or oropharynx A possible transmission cycle in nature. Am. J. Trop. Med. Hyg. 1968, 17:894-899.
46. Zeitlin L., Cone R.A., Whaley K.J. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg. Inf. Dis. 1999, 5:54-64.